Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nanocarriers for the targeted treatment of ovarian cancers.
Tomasina J, Lheureux S, Gauduchon P, Rault S, Malzert-Fréon A. Tomasina J, et al. Among authors: lheureux s. Biomaterials. 2013 Jan;34(4):1073-101. doi: 10.1016/j.biomaterials.2012.10.055. Epub 2012 Nov 20. Biomaterials. 2013. PMID: 23174141 Review.
PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L. Jebahi A, et al. Among authors: lheureux s. Cancer Lett. 2014 Jun 28;348(1-2):38-49. doi: 10.1016/j.canlet.2014.03.001. Epub 2014 Mar 18. Cancer Lett. 2014. PMID: 24650799 Free article.
Towards a new standardized method for circulating miRNAs profiling in clinical studies: Interest of the exogenous normalization to improve miRNA signature accuracy.
Vigneron N, Meryet-Figuière M, Guttin A, Issartel JP, Lambert B, Briand M, Louis MH, Vernon M, Lebailly P, Lecluse Y, Joly F, Krieger S, Lheureux S, Clarisse B, Leconte A, Gauduchon P, Poulain L, Denoyelle C. Vigneron N, et al. Among authors: lheureux s. Mol Oncol. 2016 Aug;10(7):981-92. doi: 10.1016/j.molonc.2016.03.005. Epub 2016 Apr 2. Mol Oncol. 2016. PMID: 27083764 Free PMC article.
Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.
Lheureux S, Krieger S, Weber B, Pautier P, Fabbro M, Selle F, Bourgeois H, Petit T, Lortholary A, Plantade A, Briand M, Leconte A, Richard N, Vilquin P, Clarisse B, Blanc-Fournier C, Joly F. Lheureux S, et al. Int J Gynecol Cancer. 2012 Nov;22(9):1483-8. doi: 10.1097/IGC.0b013e31826d1438. Int J Gynecol Cancer. 2012. PMID: 23027040 Clinical Trial.
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N. Lheureux S, et al. Transl Oncol. 2013 Oct 1;6(5):586-95. doi: 10.1593/tlo.13100. eCollection 2013. Transl Oncol. 2013. PMID: 24151539 Free PMC article.
161 results